Press Releases

04.29.2026

Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

04.28.2026

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

04.23.2026

Pfizer Announces 2026 Shareholder Meeting Preliminary Results

04.22.2026

Pfizer Declares Second-Quarter 2026 Dividend

04.21.2026

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

04.20.2026

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

04.09.2026

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

03.24.2026

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

03.23.2026

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

03.20.2026

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

03.19.2026

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

03.17.2026

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer